About

Yiwei Dou joined the New York University Stern School of Business as an Assistant Professor of Accounting in July 2012. His research interests relate to the causes and consequences of disclosure and financial reporting, with particular focus on bank accounting and disclosure issues. Professor Dou holds a B.A. in Accounting from Peking University, an M.A. in Economics from York University, and a Ph.D. in Accounting from the University of Toronto's Rotman School of Management. His academic background and research contributions emphasize financial reporting quality, debt contracting, and the real effects of accounting on banking and financial decision-making.

Research topics

• Finance
• Economics
• Business
• Accounting
• Computer Science
• Machine Learning
• Artificial Intelligence
• Microeconomics
• Engineering
• Monetary economics
• Econometrics

Selected publications

• Supervised Fine-tuning of Large Language Models on Financial Statements to Predict Future Earnings Changes

  SSRN Electronic Journal · 2026-01-01

  preprintOpen access1st authorCorresponding
  PublisherDOI

• Securitization, Recourse Uncertainty, and Crash Risk

  Journal of Accounting Auditing & Finance · 2025-08-12

  article1st authorCorresponding

  In this study, we examine how banks’ stock price crash risk is affected by recourse uncertainty embedded in securitizations. By recourse uncertainty, we mean the difficulty for equity market participants to assess the true extent of risk transfer between securitizing banks and investors in asset-backed securities due to the opacity of securitizations. We argue that this uncertainty facilitates the withholding and accumulation of negative news that is subsequently released at once, resulting in crashes. Using a sample of U.S. bank holding companies for the period of 2002–2015, we find that recourse uncertainty is positively associated with the future crash risk of securitizing banks. The result holds after controlling for bank intrinsic risk. We also predict and find that this association is higher for banks with poorer information environment and for the period before the adoption of SFAS 166/167, which required enhanced disclosure about securitization activities.

  PublisherDOI

• The Effect of the Current Expected Credit Loss Approach on Banks’ Lending during Stress Periods: Evidence from the COVID-19 Recession

  The Accounting Review · 2024-09-25 · 18 citations

  article

  ABSTRACT In the wake of the financial crisis, policymakers expressed the concern that the incurred loss model delays loan loss recognition to economic stress periods and thereby exacerbates banks’ lending contraction during these periods. Addressing this concern, the FASB issued Accounting Standards Update 2016-13, which requires large public banks to accrue for loan losses using the current expected credit loss (CECL) approach starting in January 2020. We hypothesize and find that banks that adopted CECL prior to the COVID-19 pandemic increased loan loss provisions and reduced loan growth during the accompanying recession more than other banks. The lending contraction is stronger for adopting banks with low regulatory capital and low loan impairment and is primarily driven by commercial loans. Lastly, we find that counties in which CECL-adopting banks have higher market share experience larger increases in unemployment rates during the recession and slower subsequent recoveries. Data Availability: Data are available from the public sources cited in the text. JEL Classifications: E32; G21; G28; M41; M48.

  PublisherDOI

• Does the CARD Act affect price responsiveness? Evidence from credit card solicitations

  Journal of Banking & Finance · 2024-05-01

  article1st authorCorresponding
  PublisherDOI

• Does Internal Control over Financial Reporting Curb Mortgage Fraud?

  SSRN Electronic Journal · 2024-01-01 · 1 citations

  articleOpen access1st authorCorresponding
  PublisherDOI

• Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

  BMC Cancer · 2023-02-06 · 19 citations

  articleOpen access

  BACKGROUND: Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. METHODS: In this phase 2 trial, patients with locally advanced or metastatic melanoma who had failed conventional treatment (chemotherapy, targeted therapy, interferon, IL-2, et al.) were recruited. The patients were administrated with Pucotenlimab of 3 mg/kg every 3 weeks until disease progression, intolerable toxicity, or treatment discontinuation for any other reasons. The primary endpoint was the overall response rate (ORR). The secondary endpoints were disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS: , 2021. The ORR was 20.17% (24/119, 95% CI, 13.370%-28.506%) based on both independent review committee (IRC) and the investigator's assessment per RECIST v1.1. The median PFS were 2.89 (95% CI, 2.037-4.074) months and 2.46 (95% CI, 2.004-4.008) months based on IRC and investigator's assessment, respectively, per RECIST v1.1. The median OS was 16.59 (95% CI, 13.963-26.973) months. Treatment-related adverse events (TRAEs) occurred in 77.3% (92/119) of the patients. The incidence of Grade ≥ 3 TRAEs was 15.1% (18/119). In addition, none of the patients died because of TRAEs. As for biomarker analysis, Eotaxin (CCL11) and MCP-1 (CCL2) were related to treatment response, while TNF-α and VEGF were related to treatment failure. CONCLUSIONS: line therapy showed promising efficacy and tolerable toxicity for patients with locally advanced or metastatic melanoma. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT04749485 (registered retrospectively on 11/02/2021).

  PublisherOA PDFDOI

• Learning from peers: Evidence from disclosure of consumer complaints

  Journal of Accounting and Economics · 2023-07-11 · 21 citations

  article1st author
  PublisherDOI

• Does the Card Act Affect Price Responsiveness? Evidence from Credit Card Solicitations

  SSRN Electronic Journal · 2023-01-01

  articleOpen access1st authorCorresponding
  PublisherDOI

• Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study

  Cell Reports Medicine · 2023-11-27 · 5 citations

  articleOpen access

  We report a multicenter, phase 2 study evaluating the efficacy of pucotenlimab, an anti-PD-1 antibody, in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, and potential biomarkers for response. Overall, 100 patients with previously treated, advanced solid tumors centrally confirmed as dMMR or MSI-H received pucotenlimab at 200 mg every 3 weeks. The most common cancer type is colorectal cancer (n = 71). With a median follow-up of 22.5 months, the objective response rate is 49.0% (95% confidence interval 38.86%-59.20%) as assessed by the independent review committee, while the median progression-free survival and overall survival have not been reached. Grade ≥3 treatment-related adverse events were observed in 18 patients. For the biomarker analysis, responders are enriched in patients with mutations in the KMT2D gene. Pucotenlimab is an effective treatment option for previously treated advanced dMMR/MSI-H solid tumors, and the predictive value of KMT2D mutation warrants further research. This study is registered with ClinicalTrials.gov: NCT03704246.

  PublisherOA PDFDOI

• Learning from Peers: Evidence from Disclosure of Consumer Complaints

  SSRN Electronic Journal · 2023-01-01 · 12 citations

  articleOpen access1st authorCorresponding
  PublisherDOI

Frequent coauthors

• Youli Zou

  16 shared

• Ole‐Kristian Hope

  BI Norwegian Business School

  12 shared

• Joshua Ronen

  New York University

  7 shared

• Geng Li

  Federal Reserve

  7 shared

• Baohua Xin

  University of Toronto

  6 shared

• Stephen G. Ryan

  New York University

  6 shared

• Feng Chen

  6 shared

• Mozaffar Khan

  6 shared